Shock Therapeutics Biotech Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Shock Therapeutics Biotech's estimated annual revenue is currently $620k per year.(i)
  • Shock Therapeutics Biotech's estimated revenue per employee is $155,000

Employee Data

  • Shock Therapeutics Biotech has 4 Employees.(i)
  • Shock Therapeutics Biotech grew their employee count by 0% last year.

Shock Therapeutics Biotech's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.3M2-60%N/AN/A
#2
$2.9M38-31%$17.5MN/A
#3
$2.9M38-33%$10.5MN/A
#4
$19.8M1280%$69.4MN/A
#5
$9.6M62-15%N/AN/A
#6
$1.4M90%N/AN/A
#7
$2.5M160%N/AN/A
#8
$7.4M480%N/AN/A
#9
$0.2M1-83%N/AN/A
#10
$1.7M1122%N/AN/A
Add Company

What Is Shock Therapeutics Biotech?

Over 5 million people die annually from trauma, tragically threatening the lives of millions more. Shock Therapeutics Biotechnologies, Inc. was founded by Donald Gann M.D. and Dan Darlington Ph.D. to bring to market a revolutionary new approach to shock treatment, which preclinical evidence suggests may significantly extend the opportunity to provide critical care. Backed by an innovative team ready to tackle the challenges ahead, STBI is positioned to revolutionize the treatment of shock. We are currently seeking angel and seed investment and strategic partners to help us complete preclinical development of our novel therapeutic over the next 2-3 years in preparation for clinical trials. Feel free to contact us at info@shockbiotech.com to learn more! *Notice: content and communication through Shock Therapeutics Biotechnoloiges, Inc. social media are not an offer to buy securities. Investment opportunities are open to accredited investors only*

keywords:N/A

N/A

Total Funding

4

Number of Employees

$620k

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.3M4N/AN/A
#2
$0.3M4-60%N/A
#3
N/A4-20%N/A
#4
$0.3M40%N/A
#5
$0.3M4-20%N/A